Bristol Myers - Celgene CVRPreferred / convertible
13F holders, Q2 2026 (June 30)15holders −2
1new positions
3sold out
$0.09avg. 13F price*
At the end of Q2 2026, 15 institutions reported holding Bristol Myers - Celgene CVR in their 13F filings, down 2 from Q1 2026. 1 opened new positions and 3 sold out. The largest holders were Transcend Capital Advisors, LLC ($10K), DAVENPORT & Co LLC ($8K) and Bank of America Corp. ($5K).
- Company
- Bristol Myers - Celgene CVR
- CUSIP
- 110122140
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $0 |
| Exits | 3 | $4K |
All 13F filers, Q1 2026 → Q2 2026: 236 shares bought and 32,300 shares sold, net −32,064 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 15 holders
| Transcend Capital Advisors, LLC | — | No change | 109,175 | $10K |
| DAVENPORT & Co LLC | — | No change | 83,970 | $8K |
| Bank of America Corp. | — | Reduce -0.0% | 50,267 | $5K |
| Purkiss Capital Advisors LLC | — | No change | 26,450 | $2K |
| Fifth Third Bancorp | — | No change | 20,000 | $2K |
| UBS Group AG | — | Reduce -25.2% | 3,121 | $281 |
| Northwestern Mutual Wealth Management Co. | — | No change | 341 | $31 |
| Wells Fargo & Company | — | Add +2000.0% | 210 | $19 |
| Rothschild Investment LLC | — | No change | 166 | $15 |
| Oakworth Capital, Inc. | — | No change | 125 | $12 |
| Morgan Stanley | — | No change | 119 | $11 |
| JPMorgan Chase & Co. | — | No change | 23 | $2 |
| Atlantic Edge Private Wealth Management, LLC | — | No change | 16 | $2 |
| Royal Bank of Canada | — | No change | 2,475 | $0 |
| Navigoe, LLC | — | New | 36 | $0 |
"% of holder's portfolio" is BRISTOL MYERS - CELGENE CVR's weight in each manager's 13F, not the share of Bristol Myers - Celgene CVR the manager owns.